Ying Huang, Legend Biotech CEO
July 7, 2022 10:08 AM EDTUpdated 01:27 PM
R&D
China
Cell/Gene Tx

Leg­end scraps tri­al of its fol­low-up au­tol­o­gous CAR-T weeks af­ter clin­i­cal hold was lift­ed

Kyle LaHucik

Senior Reporter

Six weeks af­ter get­ting its clin­i­cal hold lift­ed, Leg­end Biotech has de­cid­ed to ter­mi­nate the Phase I study of its CAR-T tar­get­ing CD4+.

The news …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times